All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your GvHD Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

DPP-4 inhibitors

DPP-4 inhibitors

Dipeptidyl peptidase 4 (DPP-4) inhibitors block function of DPP-4, a transmembrane glycoprotein receptor identical to the leucocyte surface antigen CD26. DPP-4 is involved in multiple biological processes, including insulin metabolism, bone marrow engraftment, T-cell activation, and leukocyte migration. The receptor is expressed on a variety of cells and circulates in an enzymatically active form in plasma. DPP-4 inhibition is used as anti-diabetic treatment and has also shown to reduce the incidence of acute GvHD.

Save to your areas of interest